Who is the "King of Weight Loss Drugs"? The market seems to have an answer
After the formation of a duopoly between Eli Lilly and Novo Nordisk in the GLP-1 weight loss drug market, Eli Lilly announced that its oral GLP-1 drug orforglipron showed significant efficacy and safety in Phase 3 trials. The CEO stated that orforglipron, as a once-daily pill, would provide a convenient option for users worldwide if approved, marking a shift in the GLP-1 field towards oral formulations, with Eli Lilly taking the lead in this area
After a considerable period of time forming a "dual oligopoly" situation in the "weight loss miracle drug" GLP-1 market between Eli Lilly and Novo Nordisk, the market seems to have made a judgment about the future.
Last night, Eli Lilly announced that its oral GLP-1 drug orforglipron "showed statistically significant efficacy results and safety consistent with injectable GLP-1 drugs in successful Phase 3 trials."
Eli Lilly's CEO pointed out that "as a convenient once-daily pill, orforglipron may provide a new option that, if approved, can be easily produced and launched on a large scale for people around the world."
This means that the GLP-1 field is shifting from injectable formulations developed by Eli Lilly and Novo Nordisk to convenient pill formulations, with Eli Lilly taking the lead.
